Alpha-1 Antitrypsin Deficiency — designated AATD or A1AD, OMIM #613490, an autosomal codominant inherited disorder affecting approximately 1 in 2,500 to 1 in 3,500 individuals of Northern European descent (with the ZZ genotype — PiZZ — representing the most clinically severe form, affecting approximately 100,000 individuals in the United States and 3.4 million people worldwide, of whom the vast majority — estimated at 85–90% — remain undiagnosed throughout their lifetime due to the insidious onset of symptoms, frequent misattribution of COPD to tobacco exposure alone, and the absence of routine screening programs in most countries despite AATD being the most common genetic cause of liver disease in children and the most common genetic risk factor for COPD in adults), caused by mutations in the SERPINA1 gene encoding alpha-1 antitrypsin (AAT) — a 52 kDa serine protease inhibitor (serpin) synthesized predominantly in hepatocytes and secreted into the circulation where it functions as the primary circulating inhibitor of neutrophil elastase (NE), protecting pulmonary alveolar structures from the proteolytic destruction that NE and other serine proteases inflict during the inflammatory response; the most clinically important pathological alleles are the Z allele (Glu342Lys missense mutation producing a misfolded AAT protein that polymerizes within hepatocyte endoplasmic reticulum rather than being secreted — accounting for approximately 95% of AATD-associated liver disease through ER stress, hepatocyte apoptosis, and cirrhosis development — while simultaneously reducing circulating AAT levels to approximately 15% of normal, leaving lung parenchyma severely unprotected from NE-mediated proteolysis) and the S allele (Glu264Val missense mutation producing a moderately reduced AAT level at approximately 60% of normal with milder lung and liver phenotypes than ZZ homozygosity), producing the clinically important genotypes PiZZ (both alleles Z — most severely affected, both lung and liver disease), PiSZ (one S and one Z allele — intermediate AAT levels with clinically significant lung disease risk especially with tobacco exposure, milder liver disease), PiMZ (one normal M allele and one Z allele — approximately 57% of normal AAT levels, generally not causing clinical lung disease in isolation but may modify other lung disease phenotypes), and PiMS (minimal clinical significance) — with over 120 additional pathological alleles identified, including rare null alleles that produce no detectable AAT protein and are associated with severe lung disease but no liver disease (as the null allele prevents production of the misfolded protein that accumulates in hepatocytes); the pulmonary phenotype of PiZZ AATD — severe early-onset panacinar emphysema predominantly affecting the lung bases (in contrast to the upper-lobe predominance of tobacco-associated emphysema), with FEV₁ decline accelerated compared to tobacco-matched controls, producing symptomatic COPD often by age 40–50 in smokers or age 50–60 in never-smokers — results from the unopposed action of NE and other proteases destroying alveolar walls, elastin, and the structural scaffolding of the lung; the hepatic phenotype — neonatal cholestasis (12–17% of PiZZ neonates develop clinically apparent neonatal hepatitis with jaundice and elevated liver enzymes, with the majority recovering spontaneously but a minority progressing to childhood cirrhosis requiring liver transplantation), childhood and adult cirrhosis, and hepatocellular carcinoma (HCC — occurring in approximately 8% of PiZZ patients by age 65, with an estimated annual HCC incidence of approximately 1% in PiZZ adults with established cirrhosis) — results from the toxic gain-of-function of Z-AAT polymer accumulation within hepatocytes rather than from AAT protein insufficiency; treatment in 2026 includes AAT augmentation therapy (intravenous infusion of purified pooled human plasma-derived AAT — Prolastin-C, Zemaira, Glassia, Aralast NP — administered weekly or biweekly at 60 mg/kg IV, the only approved disease-modifying therapy for the pulmonary phenotype of AATD, with biochemical efficacy demonstrated by augmentation of serum AAT levels above the protective threshold of 11 μM and with evidence from the RAPID/RAPID-Extension trials demonstrating attenuation of lung density decline on CT densitometry — the primary endpoint used to demonstrate lung structure preservation), bronchodilator therapy (LABA/LAMA/ICS as for standard COPD), pulmonary rehabilitation, smoking cessation (critical — tobacco exposure dramatically accelerates alveolar destruction in AATD), lung transplantation (single or bilateral lung transplant for end-stage AATD emphysema, with AATD representing approximately 8% of lung transplant recipients in the United States), liver transplantation (for end-stage AATD cirrhosis or for HCC within Milan criteria — liver transplantation is curative for the liver phenotype and replaces the Z-allele-bearing hepatocytes with donor hepatocytes producing normal M-allele AAT, incidentally curing the pulmonary AAT deficiency as well), and emerging pipeline therapies in 2026 including siRNA-based therapies to reduce Z-AAT production in hepatocytes (fazirsiran — ALN-AAT02 — in clinical trials), AAT polymer inhibitors, gene therapy, and small-molecule pharmacological chaperones designed to promote folding and secretion of Z-AAT rather than polymerization.
AATD technology platforms — encompassing the genetic testing platforms where SERPINA1 genotyping confirms the AATD diagnosis and identifies PiZZ, PiSZ, and other pathological genotype combinations, the pulmonology platforms managing COPD phenotype characterization, spirometry, and augmentation therapy eligibility, the augmentation therapy infusion platforms coordinating weekly or biweekly IV AAT infusions and infusion site scheduling, the home infusion nursing platforms for patients receiving augmentation therapy at home or in satellite infusion centers, the liver disease surveillance platforms managing HCC screening with ultrasound and AFP in cirrhotic PiZZ patients, the transplant evaluation platforms for lung transplant and liver transplant candidacy assessment, the clinical trial enrollment platforms for the pipeline siRNA and gene therapy studies enrolling PiZZ patients, the AATD patient registry platforms coordinating the national AATD patient registry and research biobank programs, and the multidisciplinary specialty clinic platforms at Alpha-1 Foundation-designated centers coordinating pulmonary and hepatic management, genetic counseling, family cascade screening, and augmentation therapy prescription — must maintain the availability and performance standards required by the augmentation therapy infusion scheduling continuity, HCC surveillance scheduling obligations, transplant evaluation coordination, and family cascade screening programs that define modern AATD management. This guide explains why AATD tech platforms need dedicated monitoring, what components to monitor, and how to build a monitoring strategy matched to the augmentation therapy infusion scheduling precision, liver disease HCC surveillance urgency, transplant coordination, and genetic family cascade screening that define modern alpha-1 antitrypsin deficiency care.
Why Alpha-1 Antitrypsin Deficiency Tech Platforms Require Specialized Monitoring Attention
AATD management is defined by several uniquely urgent clinical management challenges: the augmentation therapy infusion continuity imperative — weekly or biweekly IV AAT augmentation infusion scheduling interruptions deprive PiZZ patients of the only approved disease-modifying therapy for their lung disease, with each missed infusion representing a week or more of unprotected NE exposure in already-compromised alveolar tissue; the HCC surveillance urgency — PiZZ patients with established cirrhosis have an approximately 1% annual HCC incidence, and semi-annual HCC surveillance (liver ultrasound every 6 months and AFP monitoring) must be reliably scheduled and tracked to identify HCC within Milan criteria when curative resection or liver transplant is still feasible — a surveillance scheduling platform failure that delays ultrasound by 6–12 months can allow HCC to progress beyond curative treatment boundaries; the accelerated COPD exacerbation response — AATD-associated emphysema exacerbations are associated with accelerated lung function decline (FEV₁ loss per exacerbation approximately 3 times the annual background decline), making rapid exacerbation recognition and treatment initiation critical to long-term lung function preservation; and the genetic family cascade screening obligation — each PiZZ proband has a 25% probability of having PiZZ children with an AATD-positive partner, and first-degree family member SERPINA1 genotyping identifies at-risk relatives before they develop end-stage lung or liver disease.
Augmentation therapy infusion platforms must schedule and confirm weekly or biweekly AAT infusions without interruption. Missed infusions accumulate alveolar NE exposure without the protective AAT threshold. Monitor augmentation infusion scheduling platforms at 1-minute intervals during infusion scheduling hours.
HCC surveillance scheduling platforms must ensure semi-annual liver ultrasound appointments for all cirrhotic PiZZ patients. HCC detected within Milan criteria is potentially curable; beyond Milan criteria it is typically not. Monitor HCC surveillance scheduling at 1-minute intervals during clinical hours.
Pulmonary function testing platforms support augmentation therapy eligibility and COPD severity staging. Spirometry-confirmed airflow limitation (FEV₁/FVC <0.70 and FEV₁ 25–80% predicted) is required for augmentation therapy eligibility. Monitor pulmonary function platforms at 1-minute intervals during clinical hours.
Liver disease surveillance platforms must track serial liver imaging, liver biopsy pathology, and fibrosis staging for cirrhosis progression. Fibrosis progression in PiZZ patients determines transplant listing timing. Monitor liver disease surveillance platforms at 1-minute intervals during clinical hours.
SERPINA1 genotyping platforms must deliver results quickly to enable timely cascade family screening. PiZZ identification in a proband triggers immediate family cascade screening that identifies at-risk relatives before end-organ damage. Monitor genetic testing platforms at 1-minute intervals during laboratory hours.
What to Monitor on an Alpha-1 Antitrypsin Deficiency Tech Platform
Genetic Testing — SERPINA1 Genotyping and Family Cascade Screening
Monitor SERPINA1 genotyping records (PiZZ, PiSZ, PiMZ, PiMM genotype documentation; allele-specific PCR or next-generation sequencing for common and rare pathological alleles; AAT serum level documentation — PiZZ: approximately 2.5–7 μM (normal >20 μM), PiSZ: approximately 8–14 μM, PiMZ: approximately 11–17 μM; isoelectric focusing or genotyping for allele identification when serum level is borderline), rare allele identification records (null alleles — rare but associated with severe lung disease and no liver disease; F allele, I allele, and other rare pathological alleles requiring sequencing beyond standard genotyping panels; genotype-phenotype correlation documentation for rare variants), family cascade screening records (first-degree relatives of PiZZ probands — SERPINA1 genotyping of parents, siblings, and children; partner testing offered to PiZZ individuals to assess PiZZ offspring risk; genotyping of children of PiZZ patients if partner is PiMZ or PiSZ to establish PiZZ or PiSZ status before symptom onset), genetic counseling records (autosomal codominant inheritance counseling — 25% risk of PiZZ child for PiZZ × PiMZ couple; counseling for asymptomatic PiZZ individuals regarding lung protection behaviors — smoking cessation paramount, occupational dust and chemical exposure avoidance, aggressive management of respiratory infections; liver disease surveillance counseling for PiZZ relatives; reproductive counseling including carrier testing and preimplantation genetic testing options), and newborn screening integration records (AATD not universally screened at birth; advocacy documentation for newborn screening programs; pediatric hepatology referral documentation for PiZZ infants with neonatal cholestasis) at 1-minute intervals during laboratory hours.
Augmentation Therapy Management
Monitor augmentation therapy eligibility records (PiZZ or PiSZ genotype confirmation; AAT serum level below the protective threshold of 11 μM (80 mg/dL); spirometry-confirmed airflow limitation — FEV₁/FVC <0.70 post-bronchodilator; FEV₁ 25–80% predicted as per augmentation therapy indication criteria; current non-smoker status or cessation documentation; absence of IgA deficiency that would contraindicate plasma-derived product administration), infusion scheduling records (weekly or biweekly IV augmentation infusion at 60 mg/kg — Prolastin-C, Zemaira, Glassia, or Aralast NP product selection; infusion site — hospital outpatient infusion center, home infusion, or satellite infusion center; infusion nurse records; infusion date and dose confirmation records; missed infusion documentation and rescheduling records), serum AAT level monitoring records (trough AAT levels confirming augmentation to therapeutic threshold ≥11 μM pre-infusion; levels below 11 μM at trough suggesting inadequate dosing or increased clearance — dose adjustment documentation; annual AAT trough monitoring in stable patients), augmentation therapy adverse event records (infusion reactions — mild flu-like symptoms most common; anaphylaxis risk for IgA-deficient patients — IgA level pre-therapy; headache, fever, fatigue post-infusion; thrombosis risk documentation), and product shortage and supply chain records (plasma-derived AAT supply interruptions from plasma fractionation centers; alternative product substitution documentation; infusion frequency modification during supply constraints; manufacturer shortage notification records) at 1-minute intervals during infusion scheduling and clinical hours.
Pulmonary Disease Management — COPD and Emphysema
Monitor spirometry records (annual or biannual spirometry — FEV₁ baseline and trajectory; FEV₁ % predicted; FEV₁/FVC ratio; bronchodilator reversibility testing; FEV₁ decline rate on augmentation therapy versus pre-therapy baseline — target attenuation of accelerated decline), CT lung densitometry records (HRCT lung density at 15th percentile (PD15) — the primary endpoint of the RAPID trials for augmentation therapy efficacy; annual or biennial CT densitometry for AATD augmentation therapy monitoring; emphysema distribution characterization — basilar panacinar emphysema pattern; lung volume measurement), exacerbation records (COPD exacerbation — frequency, severity, healthcare utilization; systemic corticosteroid and antibiotic courses; hospitalization records for severe exacerbations; post-exacerbation FEV₁ recovery documentation; exacerbation frequency as a predictor of accelerated lung function decline in AATD), bronchodilator therapy records (LABA/LAMA/ICS combination therapy records; inhaler technique assessment; adherence monitoring; SAMA for acute exacerbations), pulmonary rehabilitation records (structured pulmonary rehabilitation program enrollment; 6-minute walk distance improvement; exercise capacity monitoring; maintenance exercise prescription after program completion), and oxygen therapy records (home oxygen indication — ambulatory oxygen saturation ≤88% on 6MWT or resting SpO2 ≤88%; oxygen flow rate and delivery device; compliance monitoring) at 1-minute intervals during clinical hours.
Liver Disease Surveillance — Fibrosis Staging and HCC Screening
Monitor liver disease evaluation records (baseline liver enzyme assessment — ALT, AST, GGT, ALP, bilirubin; liver fibrosis non-invasive markers — FIB-4, APRI, liver stiffness by transient elastography (FibroScan); liver biopsy pathology records for definitive fibrosis staging — Z-AAT polymer globule identification on PAS-D staining in hepatocytes; Metavir fibrosis stage; cirrhosis documentation — F4 fibrosis), HCC surveillance records (semi-annual liver ultrasound for all PiZZ patients with cirrhosis — the primary AATD HCC surveillance modality; AFP every 6 months concurrent with ultrasound; HCC detection size and number; Barcelona Clinic Liver Cancer (BCLC) staging for detected HCC; Milan criteria assessment for transplant eligibility), liver transplant evaluation records (end-stage liver disease listing criteria — MELD score ≥15, decompensated cirrhosis with ascites, hepatic encephalopathy, or variceal hemorrhage; HCC within Milan criteria as transplant indication; UNOS waitlist management records; liver transplant outcome records — post-transplant AAT normalization confirming curative effect), portal hypertension management records (varices — endoscopic variceal screening every 2–3 years for cirrhosis, annual for those with varices; non-selective beta-blocker primary prophylaxis for large varices; acute variceal hemorrhage management records; TIPS procedure records), and emerging liver-targeted therapy clinical trial records (siRNA therapy trials — fazirsiran enrollment records; patient eligibility documentation; trial safety monitoring records) at 1-minute intervals during clinical hours.
Home Infusion Program Monitoring
Monitor home infusion nursing records (home infusion service coordination — home health agency assignment; infusion nurse visit scheduling; IV access assessment — peripheral versus port records; pre-infusion vital sign documentation; infusion rate and product lot number records; post-infusion patient observation; adverse event documentation in home setting), infusion supply chain records (weekly or biweekly augmentation product delivery to patient home; cold chain storage compliance — product refrigeration requirement; expiration date tracking; product wastage documentation for incomplete infusions), patient self-infusion training records (patient or caregiver training for self-administered augmentation therapy; competency verification records; IV access technique documentation; emergency adverse event response training; infusion log submission), and infusion program outcomes records (home infusion adherence rate — missed home infusion documentation; infection at IV access site records; infusion-related adverse events in home setting; transition from center-based to home infusion documentation) at 1-minute intervals during infusion scheduling hours.
Lung Transplant Evaluation and Management
Monitor lung transplant candidacy records (evaluation for listing — FEV₁ <20% predicted or DLco <20% predicted or 6MWT <200 meters or rapidly progressive disease; exclusion criteria — BMI >35 kg/m², active smoking, malignancy within 5 years; UNOS lung transplant waitlist status; lung allocation score (LAS) and updates), post-lung transplant records (single versus bilateral lung transplant outcome; augmentation therapy need post-transplant — donor lungs express M-allele AAT normally, eliminating the AAT deficiency in the transplanted allograft; native lung monitoring for single-lung transplant recipients with residual native Z-allele-bearing lung; tacrolimus-based immunosuppression records; rejection biopsy results; bronchiolitis obliterans syndrome surveillance), and AATD recurrence in liver allograft records (for liver-transplant-only recipients — donor liver produces normal AAT, resolving the deficiency; pulmonary outcome documentation post-liver transplant confirming AAT normalization) at 1-minute intervals during clinical hours.
Authentication and Clinical Identity
Monitor authentication at 1-minute intervals, 24/7. AATD management coordinates across pulmonology (COPD management, augmentation therapy prescription, spirometry, CT densitometry), genetic testing and genetic counseling (SERPINA1 genotyping, family cascade screening), hepatology (liver fibrosis staging, HCC surveillance, portal hypertension management), transplant hepatology (liver transplant listing and management), transplant pulmonology (lung transplant listing and management), home infusion nursing (weekly augmentation infusion delivery), gastroenterology (variceal screening endoscopy), radiology (liver ultrasound HCC surveillance, CT lung densitometry), pathology (liver biopsy Z-AAT globule identification), and AATD specialty clinic coordinators managing multidisciplinary augmentation therapy, surveillance, and transplant programs — authentication failures block every team member required to execute infusion scheduling, HCC surveillance, pulmonary function assessment, and genetic family cascade screening.
SSL Certificates
Monitor SSL certificate expiry across all SERPINA1 genetic testing platforms, augmentation therapy infusion scheduling portals, liver disease surveillance platforms, HCC screening scheduling systems, pulmonary function reporting portals, home infusion program platforms, lung transplant coordination portals, and AATD registry systems. Certificate errors disrupt infusion scheduling (primary clinical disruption for augmentation therapy patients), HCC surveillance tracking, pulmonary function result delivery, and genetic testing portals.
HIPAA and Rare Genetic Lung and Liver Disease Privacy Considerations
AATD technology platforms handle sensitive PHI including SERPINA1 molecular genetic testing (autosomal codominant heritable mutation with implications for all first-degree family members; PiZZ genotype disclosure implications for health insurance, life insurance, and disability insurance given the established association with progressive lung and liver disease; employment implications in occupations with high dust or chemical inhalation exposure where AATD diagnosis may trigger occupational health restrictions), augmentation therapy infusion records (documentation of a weekly or biweekly IV therapy requirement with implications for employment attendance, travel planning, and disability determination), liver disease and HCC surveillance records (cirrhosis and hepatocellular carcinoma records with life insurance and disability insurance implications), and lung transplant waitlist status (organ priority status with allocation implications). The heritable SERPINA1 mutation creates genetic information privacy obligations under GINA in addition to HIPAA Privacy and Security Rule requirements.
For augmentation therapy infusion scheduling platforms — where unavailability can disrupt the only approved disease-modifying therapy for AATD pulmonary disease — availability monitoring provides operational documentation relevant to HIPAA Security Rule compliance and infusion program continuity.
Alerting Strategy for Alpha-1 Antitrypsin Deficiency Tech Platforms
Immediate clinical-hours alerting for augmentation therapy infusion scheduling platforms: Weekly or biweekly AAT infusion scheduling interruptions deprive PiZZ patients of the only approved AATD lung disease-modifying therapy. Scheduling platform failures must be detected and corrected before the next infusion window closes.
Immediate clinical-hours alerting for HCC surveillance scheduling platforms: Semi-annual liver ultrasound scheduling for cirrhotic PiZZ patients is a surveillance obligation with curative treatment window implications. Scheduling platform failures must not allow surveillance intervals to extend beyond 6 months.
Immediate laboratory-hours alerting for SERPINA1 genotyping platforms: PiZZ confirmation enables augmentation therapy initiation, HCC surveillance initiation, and family cascade screening that identifies at-risk relatives before end-organ damage.
Immediate imaging-hours alerting for liver ultrasound and CT lung densitometry platforms: HCC surveillance imaging results and CT densitometry for augmentation therapy efficacy monitoring must be accessible to clinicians managing AATD patients.
Immediate clinical-hours alerting for home infusion program coordination platforms: Home infusion scheduling, product delivery confirmation, and nursing visit coordination must function for patients receiving augmentation therapy at home.
Sustained-failure alert (10–15 minutes): AATD patient registry, clinical trial enrollment, pulmonary rehabilitation program platforms, and oxygen therapy management portals.
30-day advance warning: SSL certificates across all domains.
Vigilmon's multi-region monitoring confirms AATD platform availability from the geographies where Alpha-1 Foundation-designated AATD centers, SERPINA1 molecular genetic testing laboratories, augmentation therapy infusion centers, and AATD lung and liver transplant programs concentrate.
Status Page for Alpha-1 Antitrypsin Deficiency Care Team Communication
A real-time status page gives pulmonologists managing augmentation therapy eligibility and COPD exacerbation response, hepatologists managing liver fibrosis staging and HCC surveillance, genetic counselors managing SERPINA1 cascade family screening, home infusion nursing coordinators managing weekly infusion scheduling and product delivery, transplant pulmonologists and hepatologists managing lung and liver transplant candidacy, radiologists performing HCC surveillance liver ultrasounds and CT lung densitometry, gastroenterologists performing variceal screening endoscopy, pathologists reporting liver biopsy Z-AAT globule identification, AATD specialty center coordinators managing multidisciplinary augmentation and surveillance programs, and clinical trial coordinators enrolling PiZZ patients in siRNA and gene therapy trials immediate platform visibility without requiring inbound IT support contact.
Include the status page URL in AATD patient education materials, augmentation therapy infusion program contingency procedures, HCC surveillance scheduling backup protocols, and Alpha-1 Foundation designated center patient communication materials.
Vigilmon Setup for Alpha-1 Antitrypsin Deficiency Tech Platforms
A practical starting configuration:
| Monitor | Check Interval | Alert Channel | |---------|----------------|---------------| | Authentication | 1 min | Slack + PagerDuty (24/7) | | Augmentation therapy infusion scheduling | 1 min | Slack + PagerDuty (clinical hours) | | Home infusion program coordination | 1 min | Slack + PagerDuty (clinical hours) | | HCC surveillance scheduling (liver ultrasound every 6 months) | 1 min | Slack + PagerDuty (clinical hours) | | AFP monitoring scheduling | 1 min | Slack + PagerDuty (clinical hours) | | SERPINA1 genotyping (PiZZ / PiSZ / rare alleles) | 1 min | Slack + PagerDuty (lab hours) | | Liver ultrasound reporting platform | 1 min | Slack + PagerDuty (imaging hours) | | CT lung densitometry reporting | 1 min | Slack + PagerDuty (imaging hours) | | Spirometry and pulmonary function testing | 2 min | Slack + PagerDuty (clinical hours) | | Liver fibrosis staging (FibroScan / liver biopsy pathology) | 2 min | Slack + PagerDuty (clinical hours) | | Lung transplant candidacy and UNOS waitlist | 2 min | Slack + PagerDuty (clinical hours) | | Liver transplant candidacy and UNOS waitlist | 2 min | Slack + PagerDuty (clinical hours) | | Family cascade screening (SERPINA1 relatives) | 2 min | Slack + PagerDuty (clinical hours) | | Variceal screening endoscopy scheduling | 2 min | Slack (clinical hours) | | Pulmonary rehabilitation program | 2 min | Slack (clinical hours) | | Clinical trial enrollment (siRNA / gene therapy studies) | 2 min | Slack (business hours) | | AATD patient registry | 2 min | Slack (business hours) | | SSL: all domains | Daily | Email (30-day warning) |
Getting started:
- Create a free account at vigilmon.online
- Add authentication endpoints at 1-minute intervals with 24/7 alerting
- Configure augmentation therapy infusion scheduling platforms with immediate clinical-hours alerting — weekly AAT infusion scheduling is the operational backbone of the only approved AATD disease-modifying therapy
- Add home infusion program coordination platforms with immediate clinical-hours alerting — home infusion product delivery and nursing visit scheduling must function reliably for patients receiving augmentation at home
- Configure HCC surveillance scheduling platforms with immediate clinical-hours alerting — semi-annual liver ultrasound scheduling for cirrhotic PiZZ patients is a surveillance obligation with curative treatment window implications
- Add AFP monitoring scheduling with immediate clinical-hours alerting
- Configure SERPINA1 genotyping platforms with immediate laboratory-hours alerting — PiZZ confirmation triggers augmentation therapy eligibility, HCC surveillance initiation, and family cascade screening
- Add liver ultrasound reporting platforms with immediate imaging-hours alerting — HCC surveillance results must reach hepatologists managing cirrhotic AATD patients
- Configure CT lung densitometry reporting with immediate imaging-hours alerting — augmentation therapy efficacy monitoring depends on annual or biennial CT densitometry
- Add spirometry and pulmonary function testing platforms with sustained-failure alerting during clinical hours
- Configure liver fibrosis staging platforms with sustained-failure alerting during clinical hours
- Add lung and liver transplant candidacy and UNOS waitlist platforms with sustained-failure alerting during clinical hours
- Configure family cascade screening platforms with sustained-failure alerting during clinical hours
- Add variceal screening endoscopy scheduling and pulmonary rehabilitation platforms with sustained-failure alerting during clinical hours
- Configure clinical trial enrollment platforms for siRNA and gene therapy studies with sustained-failure alerting during business hours
- Add AATD patient registry with sustained-failure alerting during business hours
- Enable SSL certificate monitoring across all genetics, infusion scheduling, HCC surveillance, pulmonary function, transplant, and registry platforms
- Add the status page URL to AATD patient education materials, augmentation therapy infusion contingency procedures, and HCC surveillance scheduling backup protocols
Conclusion
Alpha-1 antitrypsin deficiency technology platforms are embedded in clinical decisions where augmentation therapy infusion scheduling platform availability when the infusion center coordinator opens the scheduling portal at 8:00 AM Monday to confirm the week's 47 PiZZ augmentation therapy patients — confirming their 60 mg/kg IV Prolastin-C appointments for Monday through Friday across two infusion suites and a satellite infusion location 18 miles away, adjusting for the 3 patients who need rescheduled appointments from the previous week's weather cancellations, and verifying that home infusion product deliveries have been confirmed for the 12 patients receiving augmentation at home — cannot be disrupted by infusion scheduling platform failures that turn what should be a 20-minute morning coordination task into a 3-hour phone-and-spreadsheet crisis affecting 47 patients' access to their weekly dose of the only approved therapy slowing alveolar destruction in their lungs, with each scheduling gap representing another week of neutrophil elastase activity against already-compromised alveolar tissue in patients whose FEV₁ has already declined to 45% or 38% or 29% of predicted; where HCC surveillance scheduling platform availability for the hepatologist reviewing the semi-annual HCC surveillance queue for her 63 PiZZ cirrhosis patients — confirming that each patient's 6-month liver ultrasound appointment has been scheduled within the surveillance window and flagging the 4 patients who are now 3 weeks past their scheduled ultrasound date due to appointment cancellations that were never rescheduled — cannot be disrupted by surveillance scheduling platform failures that allow the 6-month interval to extend to 9 or 12 months for patients in whom early HCC detection within Milan criteria — a 2.1 cm solitary nodule — is the difference between a resection or transplant with curative intent and a 4.6 cm lesion discovered outside Milan criteria when palliative management has become the primary option; and where SERPINA1 genotyping platform availability during the pulmonology clinic evaluation of a 38-year-old never-smoking woman referred for evaluation of unexplained COPD with FEV₁ 52% predicted and basilar-predominant emphysema on HRCT — whose AAT serum level drawn 2 weeks ago came back at 4.2 μM, well below the protective threshold — when the pulmonologist needs the SERPINA1 genotype result to confirm PiZZ status, initiate augmentation therapy eligibility documentation, refer to hepatology for liver fibrosis staging and HCC surveillance enrollment, counsel the patient about the heritable nature of her condition and the need to genotype her two adult children, and document in the chart the family cascade screening plan that will identify whether her children carry the Z allele and should undergo surveillance before they develop their own end-organ damage — cannot be disrupted by genetic testing platform failures that delay the result driving this entire cascade of care decisions. An augmentation therapy scheduling platform unavailable when 47 infusion appointments need Monday morning confirmation and rescheduling, an HCC surveillance platform failed when cirrhotic PiZZ patients' 6-month imaging windows silently expire without new appointments, a SERPINA1 genotyping platform inaccessible when the first confirmed PiZZ result should be triggering augmentation therapy initiation and a family cascade that identifies at-risk children before they develop emphysema — these are not IT incidents. They are clinical disruptions in the management of a heritable condition whose alveolar destruction accelerates every week without the augmentation therapy that the scheduling platform exists to reliably deliver, whose hepatocellular carcinoma is curable when surveillance catches it early and typically not when the surveillance platform allows the interval to slip, and whose next generation of affected family members can be identified and protected before developing end-organ damage only if the cascade screening that begins with the genotyping result is initiated promptly.
Uptime monitoring gives AATD tech teams the detection capability to identify failures within seconds, trigger immediate clinical downtime procedures, and demonstrate to Alpha-1 Foundation-designated AATD centers, SERPINA1 molecular genetic testing laboratories, augmentation therapy infusion programs, home infusion service agencies, HCC surveillance radiology programs, AATD lung and liver transplant centers, and compliance auditors that platform operational reliability matches the weekly infusion scheduling precision, semi-annual HCC surveillance scheduling urgency, genotyping result timeliness, and family cascade screening obligations of modern alpha-1 antitrypsin deficiency care.
Start monitoring your alpha-1 antitrypsin deficiency care tech platform for free at vigilmon.online — HTTP/HTTPS monitoring, multi-region consensus alerting, SSL certificate monitoring, automatic status page, Slack and webhook alerts. No agent required. No credit card.
Tags: #monitoring #alpha-1 #antitrypsin #deficiency #AATD #SERPINA1 #PiZZ #PiSZ #augmentation #therapy #Prolastin #Zemaira #AAT #infusion #emphysema #COPD #FEV1 #CT #densitometry #HCC #hepatocellular #carcinoma #liver #cirrhosis #transplant #lung #transplant #siRNA #fazirsiran #cascade #screening #genetic #HIPAA #healthtech #digitalhealth #uptime #sre